{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:20:56Z","timestamp":1771460456915,"version":"3.50.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00120-025-02560-2","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T20:56:23Z","timestamp":1743281783000},"page":"492-500","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Benignes Prostatasyndrom","Benign prostate syndrome"],"prefix":"10.1007","volume":"64","author":[{"given":"Thomas","family":"Bschleipfer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"2560_CR1","unstructured":"S2e-Leitlinie Diagnostik und Therapie des Benignen Prostatasyndroms (BPS)."},{"key":"2560_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00345-010-0638-z","volume":"29","author":"R Berges","year":"2011","unstructured":"Berges\u00a0R, Oelke\u00a0M (2011) Age-stratified normal values for prostate volume, PSA, maximum urinary flow rate, IPSS, and other LUTS\/BPH indicators in the German male community-dwelling population aged 50\u00a0years or older. World J Urol 29:171\u2013178","journal-title":"World J Urol"},{"key":"2560_CR3","first-page":"A\u00a02261","volume":"104","author":"M Oelke","year":"2007","unstructured":"Oelke\u00a0M, Klaus\u00a0JU, Laval\u00a0K\u2011U, Tunn\u00a0U (2007) Terminologie und Diagnostik des benignen Prostatasyndroms. Dtsch \u00c4rztebl 104:A\u00a02261\u2013C1934","journal-title":"Dtsch \u00c4rztebl"},{"key":"2560_CR4","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0302-2838(02)00354-8","volume":"42","author":"KM Verhamme","year":"2002","unstructured":"Verhamme\u00a0KM, Dieleman\u00a0JP, Bleumink\u00a0GS et\u00a0al (2002) Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care\u2014the Triumph project. Eur Urol 42:323\u2013328","journal-title":"Eur Urol"},{"key":"2560_CR5","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1159\/000052527","volume":"39","author":"RR Berges","year":"2001","unstructured":"Berges\u00a0RR, Pientka\u00a0L, H\u00f6fner\u00a0K et\u00a0al (2001) Male lower urinary tract symptoms and related health care seeking in Germany. Eur Urol 39:682\u2013687","journal-title":"Eur Urol"},{"key":"2560_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s00120-002-0230-2","volume":"41","author":"G Bartsch","year":"2002","unstructured":"Bartsch\u00a0G, Rittmaster\u00a0RS, Klocker\u00a0H (2002) Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia. Urologe\u00a0A 41:412\u2013424","journal-title":"Urologe A"},{"issue":"Suppl 3","key":"2560_CR7","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1038\/ijir.2008.55","volume":"20","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn\u00a0CG (2008) Pathology of benign prostatic hyperplasia. Int J Impot Res 20(Suppl 3):S11\u2013S18","journal-title":"Int J Impot Res"},{"key":"2560_CR8","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s00120-012-3083-3","volume":"52","author":"A Roosen","year":"2013","unstructured":"Roosen\u00a0A, Gratzke\u00a0C, Herrlemann\u00a0A et\u00a0al (2013) Etiology and pathophysiology of benign prostate hyperplasia. Urologe\u00a0A 52:186\u2013192","journal-title":"Urologe A"},{"key":"2560_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000474438","volume":"31","author":"X Bad\u00eda","year":"1997","unstructured":"Bad\u00eda\u00a0X, Garc\u00eda-Losa\u00a0M, Dal-R\u00e9\u00a0R (1997) Ten-language translation and harmonization of the International Prostate Symptom Score: developing a\u00a0methodology for multinational clinical trials. Eur Urol 31:129\u2013140","journal-title":"Eur Urol"},{"key":"2560_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.eururo.2016.09.026","volume":"71","author":"S Malde","year":"2017","unstructured":"Malde\u00a0S, Nambiar\u00a0AK, Umbach\u00a0R et\u00a0al (2017) Systematic review of the performance of noninvasive tests in diagnosing bladder outlet obstruction in men with lower urinary tract symptoms. Eur Urol 71:391\u2013402","journal-title":"Eur Urol"},{"key":"2560_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jama.2014.5555","volume":"312","author":"KA D\u2019Silva","year":"2014","unstructured":"D\u2019Silva\u00a0KA, Dahm\u00a0P, Wong\u00a0CL (2014) Does this man with lower urinary tract symptoms have bladder outlet obstruction?: the Rational Clinical Examination: a\u00a0systematic review. JAMA 312:535\u2013542","journal-title":"JAMA"},{"issue":"Suppl 4","key":"2560_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1464-410X.2005.05485.x","volume":"95","author":"S Milani","year":"2005","unstructured":"Milani\u00a0S, Djavan\u00a0B (2005) Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int 95(Suppl 4):29\u201336","journal-title":"BJU Int"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02560-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02560-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02560-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T09:00:18Z","timestamp":1745917218000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02560-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2560"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02560-2","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"7 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"T.\u00a0Bschleipfer: A.\u00a0Finanzielle Interessen: Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Apogepha, Bene, Dr. R.\u00a0Pfleger GmbH, ZSI, Hollister, Dr. W.\u00a0Schwabe, Janssen, Pfizer, Merck Healthcare Germany GmbH, BMS, Pierre Fabre |. \u2013\u00a0Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00c4.: Apogepha, Bene, Dr. R.\u00a0Pfleger GmbH, ZSI, Hollister, Dr. W.\u00a0Schwabe, Janssen, Pfizer, Merck Healthcare Germany GmbH, BMS, Pierre Fabre.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: CA Urologie, Klinikum Coburg GmbH, Ketschendorfer Str.\u00a033; 96450 Coburg | Mitgliedschaften: European Association of Urology (EAU), Deutsche Gesellschaft f\u00fcr Urologie (DGU), Bayerische Urologenvereinigung (BUV), Arbeitskreis \u201eBenignes Prostatasyndrom\u201c (BPS) der DGU, Arbeitskreis \u201eUrologische Funktionsdiagnostik und Urologie der Frau\u201c der DGU, Forum Urodynamicum e.\u202fV., Oberpf\u00e4lzer Urologen e.\u202fV. | Mitglied des wissenschaftlichen Beirats f\u00fcr das Hauptorgan der DGU: Die Urologie.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}